TG-1801

BIOLOGICAL2 trials

Sponsors

TG Therapeutics, Inc.

Conditions

Aggressive LymphomaB-Cell LymphomaCLLDLBCLFollicular LymphomaIndolent LymphomaMCLMarginal Zone Lymphoma

Phase 1

Study of TG-1801 in Subjects With B-Cell Lymphoma

CompletedNCT03804996

TG Therapeutics, Inc.B-Cell Lymphoma

Start: 2019-03-05End: 2024-02-21Updated: 2024-04-08

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

TerminatedNCT04806035

TG Therapeutics, Inc.Aggressive Lymphoma, CLL, DLBCL +7

Start: 2021-04-28End: 2024-06-12Updated: 2024-07-31

Related Papers

First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma

Blood2022-11-1520 citations

Abstract 3429: NI-2601, an Fc-active CD47xPD-L1 bispecific antibody that selectively targets CD47 on PD-L1-positive tumors

Cancer Research2022-06-15

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model

Experimental Hematology and Oncology2022-05-1022 citations